Ezetimibe 10 mg is generally well tolerated, with most side effects being mild and comparable to placebo in clinical trials. The most commonly reported issues are upper respiratory symptoms, diarrhea, and joint pain, each occurring in roughly 3 to 4 percent of patients. The side effect profile shifts somewhat depending on whether you take ezetimibe alone or alongside a statin.
How Ezetimibe Works
Ezetimibe lowers cholesterol differently than statins. Instead of reducing cholesterol production in the liver, it blocks a protein on the lining of your small intestine that pulls cholesterol from food into your bloodstream. By preventing this protein from doing its job, less dietary and bile-derived cholesterol reaches your liver, which prompts your body to clear more LDL (“bad”) cholesterol from your blood. This distinct mechanism is why ezetimibe is often paired with a statin for a combined effect.
Common Side Effects When Used Alone
In clinical trials, the following side effects occurred in at least 2 percent of patients taking ezetimibe by itself:
- Upper respiratory tract infection: 4.3%
- Diarrhea: 4.1%
- Joint pain: 3%
- Sinusitis: 2.8%
- Pain in an arm or leg: 2.7%
These rates were only slightly higher than what patients on a placebo experienced, which means some of these symptoms may not be caused by the drug at all. Most people taking ezetimibe alone report no notable side effects.
Common Side Effects With a Statin
When ezetimibe is combined with a statin, the side effect profile changes slightly. The most frequently reported issues in combination trials were:
- Cold symptoms (stuffy nose, sneezing, sore throat): 3.7%
- Muscle pain: 3.2%
- Upper respiratory tract infection: 2.9%
- Joint pain: 2.6%
- Diarrhea: 2.5%
Muscle pain deserves extra attention here. Statins are well known for causing muscle complaints on their own, and adding ezetimibe can modestly increase that risk. If you develop unexplained muscle soreness, weakness, or tenderness, especially with dark-colored urine, that warrants a prompt conversation with your prescriber.
Muscle and Skeletal Risks
The most serious muscle concern with any cholesterol-lowering drug is rhabdomyolysis, a rare condition where muscle tissue breaks down rapidly and can damage the kidneys. Rhabdomyolysis has been reported with ezetimibe, both alone and in combination with statins. A meta-analysis of clinical trials did not find a significant risk for rhabdomyolysis with ezetimibe monotherapy, but real-world safety reports tell a slightly different story. Adverse event data submitted to the FDA show a signal for increased risk when ezetimibe is combined with certain statins, particularly simvastatin and atorvastatin.
Age plays a role. Middle-aged patients (40 to 64) showed more rhabdomyolysis cases when using ezetimibe alone, while patients 65 and older had higher rates when ezetimibe was combined with a statin or other cholesterol-lowering agents. Other factors that raise your risk for muscle toxicity include kidney problems, an underactive thyroid, and taking higher statin doses.
Liver Enzyme Changes
Ezetimibe can cause small elevations in liver enzymes, though significant increases are uncommon. In monotherapy trials, 0.5% of patients on ezetimibe had meaningful liver enzyme elevations (three or more times the upper limit of normal), compared to 0.3% on placebo. When ezetimibe was combined with a statin, that rate rose to 1.3%, versus 0.4% for the statin alone.
If you’re taking ezetimibe with a statin, your doctor will typically check liver function tests before starting treatment and periodically afterward. On ezetimibe alone, routine liver monitoring is less of a concern, though baseline blood work is standard practice.
Drug Interactions That Can Increase Side Effects
Several medications can amplify ezetimibe’s effects or raise the risk of adverse reactions:
- Cyclosporine (an immune-suppressing drug): Dramatically increases ezetimibe levels in the blood, by roughly 240%. If you take both, your doctor will need to monitor cyclosporine levels closely, especially if you have kidney problems.
- Fibrates (another class of cholesterol drugs): Combining ezetimibe with fibrates other than fenofibrate is not recommended because the safety data are limited, and fibrates raise the risk of both gallstones and rhabdomyolysis.
- Fenofibrate: Can be used with ezetimibe but may increase the risk of gallstones. If you develop upper abdominal pain, your doctor may want to check your gallbladder.
- Cholestyramine (a bile acid binder): Reduces ezetimibe absorption by about 55%. If you take both, space them apart: take ezetimibe at least 2 hours before or 4 hours after cholestyramine.
- Warfarin: Adding ezetimibe may affect blood clotting levels, so your INR (a measure of how quickly your blood clots) should be rechecked after starting the medication.
Allergic Reactions
Hypersensitivity reactions are rare but have been reported. These range from mild skin rashes and hives to severe reactions like facial or throat swelling (angioedema) and, in very rare cases, anaphylaxis. If you develop sudden swelling, difficulty breathing, or a widespread rash after starting ezetimibe, seek immediate medical attention.
Long-Term Safety
The largest long-term study of ezetimibe, the IMPROVE-IT trial, followed over 18,000 patients with recent heart events for a median of six years. Patients took either ezetimibe plus simvastatin or simvastatin alone. The trial included prespecified safety analyses looking at cancer rates and muscle events, and found no significant long-term safety concerns with ezetimibe compared to statin therapy alone. This is reassuring for people who need to stay on the drug indefinitely.
Special Populations
Ezetimibe has been studied in adolescents aged 10 and older and appears to have similar blood levels and side effects as in adults. Limited controlled data showed no significant effect on growth, puberty, or menstrual cycles in teens. It has not been studied in children under 10.
Older adults do not need a dose adjustment. Clinical trials found no meaningful differences in safety or effectiveness between elderly and younger patients. That said, older adults who also take statins face a higher baseline risk of muscle problems, so the combination warrants closer monitoring in this group.
Ezetimibe combined with a statin is contraindicated during pregnancy and breastfeeding because statins can potentially harm fetal development, and may pass into breast milk. Ezetimibe alone has not been adequately studied in pregnant women. Anyone with active liver disease or unexplained persistent liver enzyme elevations should also avoid the ezetimibe-statin combination.